Julien Anract

Julien Anract

Auto-generated profile, based on publicly available information

Julien Anract

Department of Urology, Cochin Hospital, APHP, Paris Cité University, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2024 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
GMGeorges Mjaess
Georges Mjaess
LHLaura Haddad
Laura Haddad
TJTeddy Jabbour
Teddy Jabbour
ABArthur Baudewyns
Arthur Baudewyns
HBHenri-Alexandre Bourgeno
Henri-Alexandre Bourgeno
RDRomain Diamand
Romain Diamand

10 September 2024 in European Urology Oncology
Verified
Journal Article
Open access
JAJulien Anract
Julien Anract
CKClément Klein
Clément Klein
UPUgo Pinar
Ugo Pinar
MRMorgan Rouprêt
Morgan Rouprêt
NDNicolas Barry Delongchamps
Nicolas Barry Delongchamps
GRGrégoire Robert
Grégoire Robert
Histopathological examination of surgical specimens for benign prostatic hyperplasia (BPH) can detect incidental prostate cancer (iPCa). The aim of our study was to develop a predictive model for iPCa diagnosis for patients for whom BPH surgery is being considered. We conducted a retrospective analysis of medical files for patients who underwent BPH surgery in three academic centers between 2012 and 2022. Patients diagnosed with PCa before surgery were excluded. We calculated the global iPCa rate, and the clinically significant iPCa rate (grade group ≥2). Univariate and multivariable regression models were used to assess factors predictive of iPCa. The area under the receiver operating characteristic curve (AUC) was compared for each risk factor and for the global model. We used χ2 automated interaction detection (CHAID) for decision tree analysis. We included 2452 patients in the analysis, of whom 247 (10.0%) had iPCa, which was clinically significant in 49/247 cases (20.2%). Multivariable analysis revealed that age and prostate-specific antigen density (PSAD) were independent predictive factors for iPCa diagnosis. The AUC for a model including age and PSAD was 0.65. CHAID analysis revealed that patients with PSAD >0.1 ng/ml/cm3 had an iPCa risk of 23.4% (χ2 = 52.6; p < 0.001). For those patients, age >72 yr increased the iPCa risk to 35.4% (χ2 = 11.1, p = 0.008). Our study is mainly limited by its retrospective design. Age and PSAD were independent risk factors for iPCa diagnosis. The combination of age >72 yr and PSAD >0.1 ng/ml/cm3 was associated with an iPCa rate of 35.4%. We performed a study to find predictors of prostate cancer for patients undergoing surgery for benign enlargement of the prostate. Our model can identify patients at risk, and diagnose their cancer before surgery. This could avoid unnecessary or harmful procedures.

27 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LCLaura Nalleli Garrido Castillo
Laura Nalleli Garrido Castillo
JAJulien Anract
Julien Anract
NDNicolas Barry Delongchamps
Nicolas Barry Delongchamps
OHOlivier Huillard
Olivier Huillard
FBFatima BenMohamed
Fatima BenMohamed
PPPatrizia Paterlini-Bréchot
Patrizia Paterlini-Bréchot
Prostate cancer is the third cause of cancer-related deaths in men. Its early and reliable diagnosis is still a public health issue, generating many useless prostate biopsies. Prostate cancer cells detected in urine could be the target of a powerful test but they are considered too rare. By using an approach targeting rare cells, we have analyzed urine from 45 patients with prostate cancer and 43 healthy subjects under 50 y.o. We observed a relevant number of giant cells in patients with cancer. Giant cells, named Polyploid Giant Cancer Cells (PGCC), are thought to be involved in tumorigenesis and treatment resistance. We thus performed immune-morphological studies with cancer-related markers such as α-methylacyl-CoA racemase (AMACR), prostate-specific membrane antigen (PSMA), and telomerase reverse transcriptase (TERT) to understand if the giant cells we found are PGCC or other urinary cells. We found PGCC in the urine of 22 patients, including those with early-stage prostate cancer, and one healthy subject. Although these results are preliminary, they provide, for the first time, clinical evidence that prostate cancers release PGCC into the urine. They are expected to stimulate further studies aimed at understanding the role of urinary PGCC and their possible use as a diagnostic tool and therapeutic target.

1 September 2019 in Cell Calcium
Verified
Journal Article
Closed access
JAJulien Anract
Julien Anract
MBManon Baures
Manon Baures
NDNicolas Barry Delongchamps
Nicolas Barry Delongchamps
TCThierry Capiod
Thierry Capiod

10 October 2023 in The American Journal of Pathology
Verified
Journal Article
Closed access
LSLeïla Dos Santos
Leïla Dos Santos
FCFrancesco Carbone
Francesco Carbone
EPEmeline Pacreau
Emeline Pacreau
SDSekou Diarra
Sekou Diarra
MLMarine Luka
Marine Luka
Vincent GoffinVincent Goffin
Vincent Goffin

22 January 2022 in Life
Verified
Journal Article
Open access
PDF file
LCLaura Nalleli Garrido Castillo
Laura Nalleli Garrido Castillo
AMArnaud Méjean
Arnaud Méjean
Philippe VielhPhilippe Vielh
Philippe Vielh
JAJulien Anract
Julien Anract
ADAlessandra Decina
Alessandra Decina
PPPatrizia Paterlini-Bréchot
Patrizia Paterlini-Bréchot
There is an unmet need for reliable biomarkers to predict prostate cancer recurrence after prostatectomy in order to better guide the choice of surgical treatment. We have evaluated the predictive value of the preoperative detection of Circulating Tumor Cells (CTC) for prostate cancer recurrence after surgery. A cohort of 108 patients with non-metastatic prostate adenocarcinoma undergoing radical prostatectomy was tested for the presence of CTC before prostatectomy using ISET®. Disease recurrence was assessed by the increase in serum PSA level after prostatectomy. The following factors were assessed for statistical association with prostate cancer recurrence: the presence of CTC, serum PSA, Gleason score, and pT stage using univariate and multivariate analyses, with a mean follow-up of 34.9 months. Prostate cancer recurrence was significantly associated with the presence of at least 1 CTC at the preoperative time point (p < 0.001; Predictive value = 0.83). Conversely, the absence of prostate cancer recurrence was significantly associated with the lack of CTC detection at diagnosis (Predictive value = 1). Our multivariate analysis shows that only CTC presence is an independent risk factor associated with prostate cancer recurrence after prostatectomy (p < 0.001). Our results suggest that CTC detection by ISET® before surgery is an interesting candidate predictive marker for cancer recurrence in patients with non-metastatic PCa.